NCT02529904View on ClinicalTrials.gov

ADITEC FLU 2 STUDY: Understanding the Genetics Basis for Immune Responses to Flu Vaccines in Children and Adults

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Influenza
Interventions
BIOLOGICAL

MF59 - ATIV

"All child participants will receive 2 doses of the MF59-ATIV, with the doses separated by 28 days.~Adult participants will receive one dose of MF59-ATIV."

Trial Locations (1)

Unknown

Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine, Oxford

All Listed Sponsors
collaborator

Emory University

OTHER

collaborator

VisMederi srl

INDUSTRY

lead

University of Oxford

OTHER

NCT02529904 - ADITEC FLU 2 STUDY: Understanding the Genetics Basis for Immune Responses to Flu Vaccines in Children and Adults | Biotech Hunter | Biotech Hunter